• Je něco špatně v tomto záznamu ?

Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review

D. Vinereanu, J. Spinar, A. Pathak, D. Kozlowski,

. 2020 ; 27 (2) : e183-e193. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028421

BACKGROUND: Beta-blockers are one of the most important classes of cardiovascular agents and have been considered a cornerstone therapy in heart diseases, such as heart failure (HF) and atrial fibrillation (AF). Among different beta-blockers, metoprolol is a selective beta1-adrenergic antagonist, which has been extensively used since the 1970s. AREAS OF UNCERTAINTY: Although current guidelines include recommendations for the use of controlled-release metoprolol succinate in specific HF and AF indications, and despite extensive clinical experience with metoprolol, comparative evidence on the use of metoprolol succinate compared with other beta-blockers in these indications is limited. DATA SOURCES: We systematically reviewed the data from head-to-head studies directly comparing this compound with other beta-blockers in the treatment of HF or AF. Only clinical trials and observational studies were considered; no other limits were applied. The quality and relevance of retrieved articles were reviewed. RESULTS: A total of 18 articles of the 353 articles identified were selected for inclusion; 12 HF articles and 6 for AF. Additional references were identified from the bibliographies of retrieved articles. The studies show that oral prophylaxis with an appropriate dose of metoprolol may reduce new incidents of AF in high-risk patients. Furthermore, metoprolol succinate is associated with significant mortality and morbidity benefits in the treatment of HF. CONCLUSIONS: Despite the introduction of newer beta-blockers with differing clinical characteristics since its introduction, metoprolol succinate remains a useful drug in both HF and AF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028421
003      
CZ-PrNML
005      
20210114153821.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MJT.0000000000001043 $2 doi
035    __
$a (PubMed)31385823
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vinereanu, Dragos $u Department of Cardiology, Emergency Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
245    10
$a Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review / $c D. Vinereanu, J. Spinar, A. Pathak, D. Kozlowski,
520    9_
$a BACKGROUND: Beta-blockers are one of the most important classes of cardiovascular agents and have been considered a cornerstone therapy in heart diseases, such as heart failure (HF) and atrial fibrillation (AF). Among different beta-blockers, metoprolol is a selective beta1-adrenergic antagonist, which has been extensively used since the 1970s. AREAS OF UNCERTAINTY: Although current guidelines include recommendations for the use of controlled-release metoprolol succinate in specific HF and AF indications, and despite extensive clinical experience with metoprolol, comparative evidence on the use of metoprolol succinate compared with other beta-blockers in these indications is limited. DATA SOURCES: We systematically reviewed the data from head-to-head studies directly comparing this compound with other beta-blockers in the treatment of HF or AF. Only clinical trials and observational studies were considered; no other limits were applied. The quality and relevance of retrieved articles were reviewed. RESULTS: A total of 18 articles of the 353 articles identified were selected for inclusion; 12 HF articles and 6 for AF. Additional references were identified from the bibliographies of retrieved articles. The studies show that oral prophylaxis with an appropriate dose of metoprolol may reduce new incidents of AF in high-risk patients. Furthermore, metoprolol succinate is associated with significant mortality and morbidity benefits in the treatment of HF. CONCLUSIONS: Despite the introduction of newer beta-blockers with differing clinical characteristics since its introduction, metoprolol succinate remains a useful drug in both HF and AF.
650    _2
$a alfa-1-adrenergní receptory - antagonisté $x terapeutické užití $7 D058668
650    _2
$a beta blokátory $x terapeutické užití $7 D000319
650    _2
$a fibrilace síní $x farmakoterapie $7 D001281
650    _2
$a srdeční selhání $x farmakoterapie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a metoprolol $x terapeutické užití $7 D008790
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Spinar, Jindrich $u Department of Internal Cardiology Medicine, Faculty Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Pathak, Atul $u Department of Cardiology, Clinique Pasteur, Toulouse, France.
700    1_
$a Kozlowski, Dariusz $u Department of Cardiology and Electrotherapy, Medical University of Gdansk, Gdansk, Poland.
773    0_
$w MED00179772 $t American journal of therapeutics $x 1536-3686 $g Roč. 27, č. 2 (2020), s. e183-e193
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31385823 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114153818 $b ABA008
999    __
$a ok $b bmc $g 1608756 $s 1119601
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 27 $c 2 $d e183-e193 $e - $i 1536-3686 $m American journal of therapeutics $n Am J Ther $x MED00179772
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...